Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» rheumatoid arthritis
rheumatoid arthritis
J&J is jettisoning two of its promised blockbuster drugs, and it couldn’t come at a worse time
Endpoints
Tue, 10/17/17 - 10:26 am
JNJ
sirukumab
rheumatoid arthritis
talacotuzumab
acute myeloid leukemia
Sanofi’s Kevzara Could Be Solid Addition to Rheumatoid Arthritis
Market Realist
Mon, 10/16/17 - 10:27 am
Sanofi
Kevzara
rheumatoid arthritis
Regeneron
FDA spurns J&J’s troubled rheumatoid arthritis drug sirukumab
Endpoints
Sat, 09/23/17 - 10:01 am
FDA
JNJ
rheumatoid arthritis
sirukumab
AbbVie keen on JAK inhibitor despite safety concerns
BioPharma Dive
Tue, 09/12/17 - 04:22 pm
AbbVie
JAK inhibitors
Upadacitinib
ABT-494
rheumatoid arthritis
AbbVie reports two patient deaths in rheumatoid arthritis study
Yahoo/Reuters
Mon, 09/11/17 - 09:25 am
AbbVie
clinical trials
rheumatoid arthritis
Upadacitinib
ABT-494
Eli Lilly Preps Rejected Rheumatoid Arthritis Drug for Resubmission
Xconomy
Wed, 08/30/17 - 11:12 am
Eli Lilly
rheumatoid arthritis
FDA
baricitinib
J&J set back by negative panel vote for sirukumab
BioPharma Dive
Thu, 08/3/17 - 06:18 pm
JNJ
FDA
sirukumab
advisory panels
rheumatoid arthritis
J&J arthritis drug sirukumab raises safety concerns -FDA staff
Yahoo/Reuters
Mon, 07/31/17 - 09:43 am
JNJ
FDA
sirukumab
rheumatoid arthritis
Torpedoed by blood clots, Eli Lilly says a baricitinib comeback in rheumatoid arthritis could take years
Endpoints
Tue, 07/25/17 - 08:27 am
baricitinib
Eli Lilly
blood clots
rheumatoid arthritis
Novartis stocks drug cabinet with "Big-3" arthritis blockbusters
Yahoo/Reuters
Fri, 07/14/17 - 07:58 am
Novartis
rheumatoid arthritis
generics
Sandoz
Amgen
Enbrel
JNJ
Remicade
AbbVie
Humira
In latest setback, another Coherus partner bails out on Amgen biosimilar deal
Endpoints
Wed, 07/5/17 - 09:37 am
Coherus
Amgen
biosimilars
Daiichi Sankyo
CHS-0214
rheumatoid arthritis
Enbrel
Lilly’s Olumiant, spurned by FDA, gets nod from NICE
Fierce Pharma
Sat, 07/1/17 - 09:26 am
FDA
NICE
Europe
Eli Lilly
olumiant
rheumatoid arthritis
Humira
Pfizer’s Xeljanz: Results from the ORAL Strategy
Market Realist
Mon, 06/26/17 - 10:38 pm
Pfizer
Xeljanz
rheumatoid arthritis
J&J unveils new obesity, arthritis collaborations, shares its molecule library
Fierce Biotech
Thu, 06/15/17 - 09:43 am
JNJ
obesity
rheumatoid arthritis
molecules
molecule library
drug development
First PhIII trial of AbbVie’s upadacitinib a success
Pharma Times
Sun, 06/11/17 - 05:34 pm
AbbVie
Upadacitinib
clinical trials
rheumatoid arthritis
Abbvie Vaults First Pivotal Hurdle With Oral RA Candidate
Seeking Alpha
Fri, 06/9/17 - 11:20 am
AbbVie
rheumatoid arthritis
Upadacitinib
Sanofi, Regeneron set Kevzara up for tough rheumatoid arthritis turf battle with $39K list price
Fierce Pharma
Wed, 05/24/17 - 10:35 am
Sanofi
Regeneron
Kevzara
rheumatoid arthritis
EMA panel recommends nod for Sanofi, Regeneron's arthritis drug
Yahoo/Reuters
Sat, 04/22/17 - 01:14 pm
Europe
EMA
Sanofi
Regeneron
rheumatoid arthritis
Kevzara
Sarilumab
Lilly and Incyte's Loss Is AbbVie and Regeneron's Gain
Motley Fool
Mon, 04/17/17 - 12:09 pm
Eli Lilly
Inctye
AbbVie
Regeneron
rheumatoid arthritis
FDA
baricitinib
Humira
The FDA shot down a new rheumatoid arthritis drug — and the companies that make the drug are tumbling
Yahoo/Business Insider
Mon, 04/17/17 - 11:32 am
FDA
rheumatoid arthritis
Eli Lilly
Incyte
baricitinib
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »